{
  "item1": "ITEM 1. BUSINESS GENERAL DEVELOPMENT BUSINESS Abbott Laboratories Illinois corporation, incorporated 1900. Abbott’s* principal business discovery, development, manufacture, sale broad diversified line healthcare products. NARRATIVE DESCRIPTION BUSINESS Abbott four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, Medical Devices.",
  "item7": "ITEM 7. MANAGEMENT’S DISCUSSION ANALYSIS FINANCIAL CONDITION RESULTS OPERATIONS Abbott’s revenues derived primarily sale broad line health care products, which include medical devices, diagnostic testing products, nutritional products branded generic pharmaceuticals. These products sold under short-term receivable arrangements. Patent protection licenses, technological performance features, inclusion Abbott’s products under contract most impact which products sold; price controls, competition rebates most impact net selling prices products; measurement net sales costs impacted foreign currency translation.",
  "item2": "March 2025, Abbott obtained CE Mark its Volt™ Pulsed Field Ablation (PFA) System treat patients atrial fibrillation. May 2025, Abbott announced U.S. Food Drug Administration (FDA) approval company's Tendyne™ transcatheter mitral valve replacement (TMVR) system treat people mitral valve disease. July 2025, Abbott received regulatory approval Japan TriClip, minimally invasive treatment option patients tricuspid regurgitation, leaky tricuspid heart valve."
}